AU2003272864A1 - Composition for treting hyperlipemia - Google Patents

Composition for treting hyperlipemia

Info

Publication number
AU2003272864A1
AU2003272864A1 AU2003272864A AU2003272864A AU2003272864A1 AU 2003272864 A1 AU2003272864 A1 AU 2003272864A1 AU 2003272864 A AU2003272864 A AU 2003272864A AU 2003272864 A AU2003272864 A AU 2003272864A AU 2003272864 A1 AU2003272864 A1 AU 2003272864A1
Authority
AU
Australia
Prior art keywords
treting
hyperlipemia
composition
treting hyperlipemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003272864A
Other languages
English (en)
Inventor
Yong Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LUNAN PHARMACEUTICAL Co Ltd
Original Assignee
LUNAN PHARMACEUTICAL Co L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LUNAN PHARMACEUTICAL Co L filed Critical LUNAN PHARMACEUTICAL Co L
Publication of AU2003272864A1 publication Critical patent/AU2003272864A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003272864A 2003-01-20 2003-10-13 Composition for treting hyperlipemia Abandoned AU2003272864A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN03100575.6 2003-01-20
CNB031005756A CN1205934C (zh) 2003-01-20 2003-01-20 治疗高血脂症的组合物
PCT/CN2003/000855 WO2004064840A1 (fr) 2003-01-20 2003-10-13 Composition pour le traitement de l'hyperlipidemie

Publications (1)

Publication Number Publication Date
AU2003272864A1 true AU2003272864A1 (en) 2004-08-13

Family

ID=4789856

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003272864A Abandoned AU2003272864A1 (en) 2003-01-20 2003-10-13 Composition for treting hyperlipemia

Country Status (3)

Country Link
CN (1) CN1205934C (zh)
AU (1) AU2003272864A1 (zh)
WO (1) WO2004064840A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1692906A (zh) * 2004-04-30 2005-11-09 鲁南制药集团股份有限公司 治疗高血脂症的组合物
CN100358526C (zh) * 2004-05-08 2008-01-02 鲁南制药集团股份有限公司 治疗高血脂症的组合物
WO2005115393A1 (fr) * 2004-05-25 2005-12-08 Lunan Pharmaceutical Group Corporation Composition anti-hyperlipemie
MX2007003735A (es) 2004-09-28 2007-04-23 Otsuka Pharma Co Ltd Compuesto de carboestirilo.
HU227696B1 (en) 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
CN101352425B (zh) * 2007-07-27 2010-11-10 鲁南制药集团股份有限公司 一种复方渗透泵控释制剂及其制备方法
CN101385731B (zh) * 2007-09-10 2010-12-15 鲁南制药集团股份有限公司 治疗高脂血症的渗透泵控释制剂组合物及其制备方法
CN101385729B (zh) * 2007-09-10 2010-07-21 鲁南制药集团股份有限公司 一种治疗高脂血症的渗透泵控释制剂组合物及其制备方法
CN101385730B (zh) * 2007-09-10 2010-07-21 鲁南制药集团股份有限公司 一种治疗高脂血症的渗透泵控释制剂组合物及其制备方法
CN101559058B (zh) * 2008-04-16 2011-07-20 北京本草天源药物研究院 一种治疗血脂异常的药物组合物
CN101590051B (zh) * 2008-05-29 2012-11-07 北京奥萨医药研究中心有限公司 含有烟酸、HMG-CoA还原酶抑制剂和α-糖苷酶抑制剂的药物组合物
CN101985039A (zh) * 2010-11-08 2011-03-16 北京阜康仁生物制药科技有限公司 一种用于抗血栓的药物组合物
CN105362586A (zh) * 2015-12-01 2016-03-02 青岛麦瑞特医药技术有限公司 一种治疗老年尿失禁的药物组合物
CN105616481A (zh) * 2016-03-03 2016-06-01 广东福寿仙生物科技有限公司 一种降血脂中西药制剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
CA2003478A1 (en) * 1988-12-12 1990-06-12 Leonard G. Dennick Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination

Also Published As

Publication number Publication date
WO2004064840A1 (fr) 2004-08-05
CN1205934C (zh) 2005-06-15
CN1425374A (zh) 2003-06-25

Similar Documents

Publication Publication Date Title
AU2003224597A1 (en) Organic compositions
AU2003285288A1 (en) Composition
AU2003279366A1 (en) Novel compounds
AU2003300056A1 (en) Organic compositions
AU2002950744A0 (en) Composition
EP1608691B8 (en) Crosslinking composition
AU2003235708A1 (en) Polytartrate composition
AU2003281307A1 (en) Solvent composition
AU2003272864A1 (en) Composition for treting hyperlipemia
AU2003303648A1 (en) Novel 5-hydroxyindole-3-carboxylate derivatives
AU2003208411A1 (en) Anti-glycolytic composition
AU2003269904A1 (en) Antigen-polymer compositions
AU2003202905A1 (en) Organic composition
EP1479740B8 (en) Ink composition
AU2003100144A4 (en) Lousicide composition
AU2003208841A1 (en) Gasolinen compositions
AU2003229087A1 (en) Single-crystal-like materials
AU2003251259A1 (en) Novel compounds
AU2003261809A1 (en) Solvent composition
AU2003268772A1 (en) Oil-barrier composition
AU2003256465A1 (en) Dispersant composition
AU2003216382A1 (en) Idothyronine compositions
AU2003904355A0 (en) A composition
AU2003284506A1 (en) Coolant composition
AU2003275633A1 (en) Remedy for hyperlipemia

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase